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Tumor-derived TGF- inhibits mitochondrial respiration to suppress IFN- production by 
human CD4+ T cells 
One sentence summary: 
TGF- in human malignant effusions inhibits CD4+ T cell production of IFN-, a key anti-tumor 
cytokine, by inhibition of mitochondrial complex V and suppression of cellular ATP-coupled 
respiration. 
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Abstract 
TGF- is produced by tumors, and increased levels are associated with poor survival. Functionally, 
TGF--mediated suppression of anti-tumor T cell responses contributes to tumor growth and survival. 
However, TGF- can also have tumor suppressive activity, and dissecting cell-type specific 
molecular effects may decisively inform therapeutic strategies targeting this cytokine. Here we 
investigated the mechanisms involved in suppression of a key anti-tumor CD4+ T cell function –
interferon- (IFN-) production– by tumor-derived TGF- in human peripheral and tumor-associated 
lymphocytes. Suppression required expression and phosphorylation of TGF- signaling proteins 
(Smad proteins), but not their nuclear translocation, and was dependent on oxygen availability –
suggesting a metabolic basis. Indeed, Smad proteins were detected in mitochondria of CD4+ T cells, 
where they were phosphorylated upon TGF- exposure. Phosphorylated Smad proteins were also 
detected ex vivo in mitochondria of tumor-associated lymphocytes. TGF- treatment significantly 
impaired ATP-coupled respiration of CD4+ T cells, and specifically mitochondrial complex V (ATP-
Synthase) activity. Finally, inhibition of ATP-Synthase per se was sufficient to impair IFN- 
production. These results demonstrate that TGF- targets T cell metabolism directly, thus diminishing 
their function (metabolic paralysis), with relevance to human anti-tumor immunity. 
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Introduction 
Transforming growth factor 1 (TGF-) plays a complex role in tumor initiation and 
progression, demonstrating both tumor-suppressive and tumor-promoting activities. Tumor-
suppressive activities of TGF- are linked to its capacity to inhibit cellular proliferation, induce 
apoptosis and suppress growth factor expression (1). However, many tumor types produce TGF- in 
large quantities, and this is associated with metastasis and poor patient prognosis. Tumor-promoting 
activities of TGF- include dysregulation of the cell cycle, increased extracellular matrix formation, 
angiogenesis and, importantly, inhibition of anti-tumor T cell immunity (1). 
A critical immune-regulatory role for TGF- was established by the lethal inflammatory 
phenotype of TGF- deficient mice (2). T cells are critical targets of TGF-, as specific deletion of 
the TGF-RII on T cells phenocopied this disease (3, 4). Indeed, TGF- influences thymic selection 
and differentiation of mature T cells to promote central and peripheral immune tolerance (5-7). TGF-
 inhibits T cell proliferation and suppresses differentiation and function of cytotoxic CD8+ T cells, 
as well as pro-inflammatory “T helper” (Th)1 and Th2 CD4+ T cell subsets. Conversely, TGF- 
promotes expression of the transcription factor FoxP3, driving regulatory T cell (TReg) development. 
However, reconstitution of TRegs could only partially rescue disease in T cell TGF-βRII deficient 
mice (4, 5), indicating the significance of direct T cell inhibitory activities of TGF-. 
Because of its tumor-promoting and immune-regulatory roles, TGF- may present a valuable 
therapeutic target in cancer. Indeed, small molecule inhibitors of TGF- receptor signaling, TGF--
neutralizing antibodies and oligonucleotides targeting TGF- are currently under investigation in 
clinical trials (8). However, completely inhibiting TGF- activity may also impair its beneficial 
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tumor-suppressive activity. A deeper understanding of TGF- signaling and cellular effects is 
therefore required to inform precise and context-appropriate therapeutic approaches. 
TGF- binds its tetrameric receptor complex of TGF-RI and TGF-RII to trigger receptor 
serine/threonine kinase activity and phosphorylation of downstream targets. In the canonical model 
of TGF- signaling, phosphorylated Smad2 and Smad3 interact with Smad4. Subsequent nuclear 
translocation of this trimeric complex leads to transcriptional gene regulation (9). Smad-independent 
TGF- signaling pathways are also described, involving PI(3)-kinase, p38 kinase and small GTPases 
such as RhoA and Rock (1), and recently a TGF--independent role for Smad4 in T cells was 
identified (10). In addition to transcriptional regulation, direct interaction of Smads with other 
proteins has also been identified (11). These include p53/p63 complexes, inhibiting their tumor-
suppressive function (1), as well as subunits of the mitochondrial electron transport chain (ETC), 
which was reported to increase ROS production and promote apoptosis (12). Here we assessed the 
impact of tumor-derived TGF- on human CD4+ T cell effector function and identified TGF- 
mediated cellular mechanisms which may inform targeted therapeutic interventions to rescue 
suppression of anti-tumor immunity by TGF-. 
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Results 
The tumor microenvironment can be rich in TGF-, which is implicated in preventing 
effective anti-tumor T cell responses. We quantified TGF- in a panel of eleven effusion fluids from 
a range of human metastatic tumors (Tbl. 1, Fig. 1A) and assessed their effect on production of 
interferon (IFN)- by effector memory (EM) CD4+ T cells, which comprise the majority of tumor-
infiltrating CD4+ T lymphocytes (13). Specifically, activated human EM (CD127+CD25–CD45RA–
CCR7–) CD4+ T cells from healthy donors were stimulated for 16 hours in the presence of tumor 
effusion fluid (50% with 50% serum-free medium to buffer pH), and additionally either an isotype 
control antibody or a specific antibody to neutralize TGF-. These assays identified that 
neutralization of TGF- in effusion fluids increased the frequency of EM CD4+ T cells expressing 
IFN-, with a strong positive correlation between the concentration of TGF- in the respective 
effusions and the capacity to rescue IFN- production by blocking this cytokine (Fig. 1B). TGF- is 
reported to signal by both canonical pathways involving Smad phosphorylation, nuclear translocation 
and transcriptional regulation, as well as non-canonical Smad-dependent and -independent pathways 
(1, 9). Understanding the relative importance of the respective signaling mechanisms in driving a 
given outcome should inform therapeutic strategies that aim at targeting TGF- signaling to restore 
T cell function. To investigate the cellular mechanisms involved in TGF--mediated suppression of 
IFN-, effusion fluids with TGF--dependent inhibitory capacity (n=8) were further characterized. 
The effect of neutralizing TGF- in these effusions on the frequency of IFN--producing cells, and 
on total IFN- secreted into the supernatant, is shown in Figure 1C-F. We then interrogated the 
requirement for Smad phosphorylation and nuclear translocation in our system, using 
pharmacological inhibitors –namely the activin receptor-like kinase (ALK) inhibitor SB-431542, 
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which prevents Smad phosphorylation (14), and ivermectin, which inhibits the importin / nuclear 
transporters involved in Smad nuclear translocation (Refs. 15, 16, and Suppl. Fig 1). These 
experiments showed that suppression of IFN- production by tumor effusions was abrogated by 
inhibition of Smad phosphorylation, but, conversely, was unaffected by inhibiting nuclear Smad 
import with ivermectin (Fig. 1G-H). Thus, Smad phosphorylation, but not nuclear translocation, was 
required for the immune-suppressive effect of tumor-derived TGF- on EM CD4+ T cells. Inhibition 
of IFN- expression was also not observed under hypoxic conditions (Fig. 1I-J), a hint that the 
observed nuclear translocation-independent mechanism may have a metabolic basis. 
To directly investigate whether TGF- affects the metabolism of CD4+ T cells, we next 
exposed activated EM CD4+ T cells to TGF- for 16 hours and then measured their respiratory and 
glycolytic capacity (for a detailed explanation of metabolic parameters refer to Suppl. Fig. 2A-D). 
This revealed that treatment with TGF- resulted in significantly decreased basal and ATP-coupled 
oxygen consumption rates (OCR) (by approximately 30 and 40% respectively), with no change in 
spare respiratory capacity (SRC) (Fig. 2A-D). Comparison of ATP-coupled vs. FCCP-stimulated 
maximal OCR identified that the TGF- mediated suppression of ATP-coupled OCR was partially 
rescued by FCCP treatment (with 40% suppression decreasing to ~20%), implying that a functional 
inhibition of the electron transport chain (ETC) may be at least partly responsible. A modest, yet 
consistent, decrease of basal and maximal rates of glycolysis was also observed (Fig. 2F-H). The 
impact of TGF- on mitochondrial respiration was, however, greater than that on glycolysis, as 
evidenced by a decreased OCR/ECAR ratio (Fig. 2I). Of note, inhibition of basal and ATP-coupled 
OCR by TGF- was unhindered in the presence of ivermectin, but did not occur when treating cells 
with SB-431542 – indicating that Smad phosphorylation, but not nuclear translocation, was required 
also for these metabolic effects (Suppl. Fig 3A-B). The role of Smad2 in TGF-β-mediated metabolic 
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suppression was further confirmed by genetic manipulation of its expression. Smad2 protein 
abundance was efficiently reduced in primary CD4+ T cells and Jurkat T cells (by approx. 75% and 
60% respectively – Suppl. Fig 4) by transfection with siRNA. Subsequent metabolic analyses of 
these cells revealed that TGF-β exposure of cells treated with Smad2 siRNA achieved significantly 
less suppression of ATP-coupled respiration than in cells treated with control siRNA. Again 
glycolysis was only modestly affected, with no significant difference between control- and Smad2-
siRNA treated cells (Figure 2J-K). TGF- did not impact the viability of activated EM CD4+ T cells 
at this time point (Fig. 2L). 
Activation of naïve murine CD4+ T cells in the presence of TGF- for prolonged periods of 
time –to induce differentiation of regulatory T cells (TReg)– has been reported to increase, rather 
than decrease, mitochondrial respiratory capacity, further associated with increased fatty acid 
oxidation (FAO) (17). Indeed, and contrary to the reduction in ATP-coupled respiration observed 
when treating activated EM CD4+ T cells with TGF- for only 16 hours (Fig. 2), we also observed 
that anti-CD3/anti-CD28 mAb mediated activation of bulk human CD4+ T cells for 72 hours in the 
presence of 2 ng/ml of TGF- (which increased the frequency of FoxP3+ TReg (Suppl. Fig. 5A)), 
increased mitochondrial membrane potential (ΔΨm) and SRC (Suppl. Fig. 5B-D). Rates of 
glycolysis were not influenced by activation of CD4+ T cells in the presence of TGF- (Suppl. Fig. 
5E,F). TGF- thus differentially impacted mitochondrial function depending on the duration of 
exposure. 
One mechanism by which TGF- may inhibit CD4+ T cell ATP-coupled respiration is 
modulation of the activity of mechanistic target of rapamycin (mTOR) complex 1 (mTORC1), a 
master regulator of cellular metabolism. To interrogate this, we first assessed mTORC1 activity by 
studying phosphorylation of a key target protein, p70S6 kinase (p70S6K). These experiments 
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revealed that TGF- treatment of activated total CD4+ T cells did significantly suppress mTORC1 
activity, which was dependent upon Smad2 phosphorylation (Suppl. Fig 6A-B). Therefore, we next 
interrogated the extent to which mTORC1 inhibition was responsible for the observed effects of TGF-
 on CD4+ T cell metabolism, by comparison with the mTORC1 inhibitor rapamycin. These assays 
identified that both TGF- and rapamycin significantly reduced ATP-coupled oxygen consumption 
of activated CD4+ T cells, and furthermore that there was an additive effect in cells treated with both 
compounds – indicating mTORC1-independent effects of TGF- on mitochondrial function (Suppl. 
Fig 6C-D), in agreement with the data in Fig. 2E, which suggested a functional ETC inhibition. 
Effects of rapamycin and TGF- on glycolysis were again more modest and furthermore there was 
no additive effect of both compounds (Suppl. Fig 6C-D). 
To further dissect these mTORC1-independent effects, we first investigated whether TGF- 
treatment impacted the transcription of a panel of master regulators of mitochondrial biogenesis. 
Following 5 or 24 hours of treatment with TGF-, mRNA levels of these gene products in total, 
activated CD4+ T cells were unaffected (Fig. 3A). Consistent with this, exposure to TGF- for 24 
hours also did not affect overall expression levels of ETC complexes I-V (Fig. 3B). These data 
therefore also pointed to a potential direct inhibition of mitochondrial function, rather than a 
transcriptional regulation of mitochondrial component expression. Based on their structure, TGF- 
signaling proteins (Smad 2, 3 and 4) are predicted to localize to mitochondria (18) and have been 
detected in mitochondrial fractions of non-lymphoid cells (12). We therefore examined subcellular 
localization of pSmad2/3 by imaging flow cytometry (Fig. 3C). CD4+ T cells were, in addition to 
pSmad2/3, stained with mitotracker red (MTR) and 4,6-diamidino-2-phenylindole (DAPI) to identify 
mitochondria and nuclei, respectively. Analysis of fluorochrome abundance in these cellular 
compartments confirmed a significant enrichment of MTR in mitochondria compared to the nuclear 
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marker DAPI, and furthermore identified that pSmad2/3 was enriched in mitochondria compared to 
DAPI (Fig. 3D). Comparison of control and TGF- treated cells revealed increased abundance of 
pSmad2/3 upon TGF- treatment in both nuclear and mitochondrial compartments, which was 
comparable in terms of fold increase (Fig. 3E,F). These data indicated that phosphorylated Smad 
proteins were present in mitochondria of CD4+ T cells, and phosphorylation was increased upon TGF-
 treatment. Evidence for in vivo relevance of mitochondrial pSmad2/3 was obtained by studying 
tumor-associated CD4+ T cells (recovered from the effusion fluids utilized above). Direct ex vivo 
staining of pSmad2/3 in these cells, and analysis by flow cytometry, revealed that abundance of 
pSmad2/3 in tumor-associated CD4+ T cells closely reflected the TGF- concentration of the 
respective effusion fluid from which the cells were recovered (Fig. 3G/Fig.1A, Tbl. 1). Additionally, 
imaging analysis identified a similar enrichment of pSmad2/3 in mitochondria of tumor-associated 
CD4+ T cells compared to DAPI, as was observed for peripheral counterparts in vitro (Fig. 3H,I). 
To define the molecular basis through which mitochondrial Smad proteins impacted CD4+ T 
cell respiration, we assessed what aspect of mitochondrial function was impaired. The function of 
ETC complexes I, II, III and IV was assessed by measuring oxygen consumption rates of isolated 
mitochondria in response to the provision of specific substrates or electron donors for each complex 
(Suppl. Fig. 7A-D). Performing such analyses on mitochondria isolated from activated EM CD4+ T 
cells pre-cultured for 5 hours in control or TGF- containing medium demonstrated decreased oxygen 
consumption in response to all four substrates/electron donors (Fig. 4A, Suppl. Fig. 7A-D). This 
implied either (i) decreased functionality of all ETC complexes, (ii) decreased function of complex 
IV (which consumes the oxygen that is measured), or (iii) decreased function of complex V, ATP-
Synthase, which may subsequently impact efficiency of the entire ETC – and cannot be directly 
measured in these experiments. To answer this question we next undertook biochemical studies 
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selectively measuring activity of complex I, II, IV or V, using cell lysates of control and TGF- 
treated, activated total CD4+ T cells. In TGF- treated cells, these assays revealed no inhibition of 
the function of complexes I, II and IV, but significant inhibition of complex V activity (Fig. 4B). 
Consistent with an inhibition of complex V activity, TGF-β treatment also caused a significant 
increase in T cell mitochondrial membrane potential (Fig. 4C). 
Both glycolytic and mitochondrial functionality of T cells critically underpin key immune 
functions (19). We next probed the impact of metabolic inhibition by TGF- on the immune function 
of EM CD4+ T cells – specifically on IFN- production, which we had observed to be significantly 
impaired by TGF- present in tumor effusions (Fig. 1). Indeed, performing multiplex cytokine 
analyses we confirmed that TGF- treatment most profoundly inhibited secretion of IFN- in EM 
CD4+ T cells, compared to other cytokines (interleukin (IL)-10, IL-17) (Fig. 5A). Inhibition of IFN-
 secretion by TGF- in other subsets of activated CD4+ T cells (naïve and central memory) was less 
marked and did not reach statistical significance (Suppl. Fig 8A), which was consistent with lower 
expression of TGF-RII and less TGF--induced Smad2/3 phosphorylation in these cells (Suppl. Fig 
8B-E). TGF- can inhibit IFN- expression by transcriptional repression of the TBX21 (T-bet) and 
IFNG (IFN-) genes (9, 20). However, we observed that nuclear translocation was not required for 
TGF- dependent inhibition of IFN- expression by tumor effusions (Fig. 1). To further define TGF-
 mediated transcriptional vs. metabolic regulation of IFN- production, we again blocked nuclear 
import of Smad proteins using the nuclear import inhibitor, ivermectin, and compared its effects to 
inhibition of Smad phosphorylation with SB-431542. We first confirmed, by flow cytometric analysis 
of pSmad2/3 abundance, that treatment with SB-431542 – but not ivermectin – prevented TGF- 
mediated phosphorylation of Smad2/3 (Fig. 5B). Next, having verified by imaging flow cytometry 
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and imaging that ivermectin and SB-431542 both inhibited nuclear pSmad2/3 import (Fig. 5C, Suppl. 
Fig. 1), we furthermore confirmed that both inhibitors prevented transcriptional repression of T-bet 
(TBX21), and IFN- (IFNG) (Fig. 5D). We then assessed IFN- production and observed that TGF-
 treatment still inhibited IFN- production even in the presence of ivermectin, which blocked nuclear 
import of phosphorylated Smad proteins and thus transcriptional effects of TGF-. However, 
inhibiting Smad phosphorylation with SB-431542 abolished the inhibitory effects of TGF- on IFN-
 production (Fig. 5E), indicating critical roles for phosphorylated Smad proteins in inhibiting IFN-
 production by EM CD4+ T cell, by transcription-independent mechanisms. These experiments 
therefore concur with our initial observations using tumor effusions. We then aimed to verify the 
relevance of TGF--mediated suppression of IFN- in tumor-associated T cells. To do so, we assessed 
IFN- production by tumor-associated T cells (n=3 independent donors), activated in presence of 
TGF- at the concentration that was present in their respective effusion fluids, plus either an isotype 
control or TGF--neutralizing mAb (to inactivate any TGF- produced by tumor cells in the culture). 
Aligning with the in vitro functional and mechanistic experiments, these assays confirmed that 
effusion-level TGF- also inhibited tumor-associated T cells directly ex vivo, compared to cultures 
treated with TGF- neutralization, with a magnitude that reflected the respective effusion TGF- 
concentration (Fig. 5F left panel/Fig. 1A, Tbl. 1). Furthermore, in two donors where sufficient cells 
were available, we additionally observed that TGF--mediated IFN- suppression occurred despite 
blockade of Smad nuclear import with ivermectin (Fig. 5F right panel). 
Next, we assessed whether inhibition of complex V and other ETC complexes per se could 
impact IFN- production by EM CD4+ T cells, by treating cells with specific inhibitors. Indeed, 
complex V inhibition with oligomycin was sufficient to decrease both the percentage of EM CD4+ T 
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cells producing IFN-, as well as the total amount of IFN- secreted by these cells (Fig. 5G,H), which 
was also true for inhibition of complexes I, II III and IV (Suppl. Fig. 9A-D). Unhindered 
mitochondrial ETC function was thus required for IFN- production by EM CD4+ T cells, and seems 
to be specifically targeted –at the level of complex V– by TGF- signaling. Notably, oligomycin 
treatment did not achieve the same degree of IFN- suppression TGF- treatment – indicating that 
TGF- acts by additional pathways in the cytoplasm to suppress IFN- production (for example 
inhibition of mTORC1). However, when cells were treated with TGF-, no additional suppression of 
IFN-γ could be achieved by adding in oligomycin, suggesting the ETC-linked IFN- was already 
maximally suppressed by TGF-β treatment (Fig. 5I). Further confirmation that inhibition of 
mitochondrial function played an important role in the suppression of IFN- production by TGF- in 
EM CD4+ T cells, came from observations that IFN- expression was not inhibited by TGF- under 
hypoxic conditions, which was also true for the complex V inhibitor, oligomycin (Fig. 5J-K), and 
for the tumor effusions (Fig. 1I-J). 
To assess whether direct metabolic inhibition, driven by TGF-, was recapitulated using 
clinical samples rich in this cytokine, we assessed the capacity of two tumor effusions – described in 
Supplementary Table 1/Figure 1 – to impact metabolic parameters of activated EM CD4+ T cells. 
These assays confirmed that activated EM cells, cultured in the presence of effusion fluid with an 
isotype control antibody, had reduced ATP-coupled respiration compared to cells cultured identically, 
yet in the presence of a specific mAb to neutralize TGF- (Fig. 6A,B). Basal rates of glycolysis were 
also slightly reduced in these cells, yet calculation of OCR/ECAR ratios again indicated the effect on 
respiration to be greater (Fig. 6C). 
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Discussion 
 
Production of TGF- by tumors is associated with metastasis and poor patient prognosis. This 
is related to both tumor-promoting and immune-inhibitory effects of TGF-, but tumor-suppressive 
activities of TGF- are also described (1). Thus, while TGF- is a promising therapeutic target for 
cancer, fully exploiting its potential will require a precise and context-specific understanding of its 
cellular effects. 
Here we investigated the cellular mechanisms involved in TGF- mediated inhibition of an 
important CD4+ T cell anti-tumor function, IFN- production (21). We found that effusions from 
metastatic human tumors impaired IFN- production in a TGF--dependent manner, and furthermore 
that TGF- used at concentrations observed ex vivo suppressed IFN- production of human tumor-
associated T cells. This immune-suppression occurred by a mechanism requiring phosphorylation of 
the Smad signaling proteins, but, surprisingly, not their nuclear translocation. Rather, inhibition was 
dependent on environmental oxygen abundance and indeed we identified that Smad proteins were 
present and phosphorylated within mitochondria of T cells exposed to TGF- both in vitro and in 
vivo and that TGF- treatment significantly impaired both complex V activity and ATP-coupled 
respiration –the latter in a Smad2 dependent manner. Additionally, complex V inhibition per se was 
sufficient to impair IFN- production by CD4+ T cells. 
TGF- signaling has previously been reported to impact metabolism at both the organismal 
and cellular level. Increased hypothalamic TGF- in obesity and aging has been linked to systemic 
glucose intolerance (22). More directly, mice deficient in Smad3 or treated with TGF- neutralizing 
antibodies were protected from diet-induced obesity and diabetes, which was associated with 
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‘browning’ of white adipocytes, heightened mitochondrial biogenesis and augmented respiratory 
capacity of these cells (23). We found no transcriptional regulation of a panel of transcription factors 
orchestrating mitochondrial biogenesis after 5 and 24 hours of treatment with TGF-. However, 
activation of total CD4+ T cells for 72 hours in presence of TGF-, to promote TReg differentiation, 
did increase mitochondrial respiratory capacity and FAO –consistent with previous reports (17)– 
indicating duration-dependent effects of TGF- on CD4+ T cells. At the cellular level, TGF- itself 
has previously been detected in the mitochondria of cardiomyocytes, hepatocytes and T cells (24-26). 
T cells lacking TGF- have abnormal mitochondrial morphology, indicating a possible homeostatic 
role for TGF- in mitochondrial biogenesis and/or dynamics (26). To date, cell-intrinsic vs. autocrine 
signaling-dependent effects of TGF- have, however, not been assessed. Functionally, TGF- 
exposure has been reported to decrease mitochondrial membrane potential in human fibroblasts (27), 
electron transport chain (ETC) complex IV activity in murine lung epithelial cells (28, 29), and 
function of complex IV in murine renal podocytes (30). TGF- also regulates cellular metabolism 
through effects on mTOR complex I (mTORC1) activity. We confirmed inhibition of mTORC1 in 
human CD4+ T cells by TGF-, and furthermore that direct mTORC1 inactivation significantly 
repressed CD4+ T cell respiration. However we additionally showed –by combining TGF- treatment 
with direct mTORC1 inhibition– that TGF- has significant effects on CD4+ T cell mitochondrial 
respiration independent of mTORC1 regulation. TGF- was also reported to impair mitochondrial 
calcium uptake in renal arteriolar cells (31). Since calcium flux is critical for T cell signaling, this 
observation is of particular interest. Smad signaling proteins, based on their structure, are predicted 
to localize to mitochondria (18), and indeed Smad 3, 4 and 5 have been detected in mitochondria of 
various cell types –not including immune cells (12, 18). Our study now links complex V-associated 
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Smad and TGF- driven phosphorylation thereof, with mitochondrial suppression and impaired 
immune functionality. 
Activation of T cells drives important changes in cellular metabolism which are critical for 
their effector function, through bioenergetic and non-bioenergetic mechanisms (32, 33). The 
signaling pathways that drive metabolic reprograming during T cell activation are quite well 
characterized and involve the PI(3)-kinase–Akt–mTOR axis, as well as the transcription factors c-
Myc, estrogen-related receptor α (ERR-α) and AP4 (19). Signaling from inhibitory receptors, such as 
CTLA-4 and PD-1, antagonizes these pathways to limit metabolic reprogramming (34). T cell 
effector function is also limited in the tumor microenvironment by competition for metabolic 
precursors (35, 36). To date, cell extrinsic signals that directly modulate T cell metabolism to mediate 
an immune-regulatory effect have not been described. For TGF-, such a role is consistent with both 
its immune-regulatory function and its abundance in malignantly transformed tissue sites. Selectively 
alleviating T cell metabolic paralysis induced by TGF-, while maintaining transcriptional activity 
with postulated anti-tumor activity, might prove to be an effective strategy for cancer therapy. 
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Materials and Methods  
Study Design 
The objective of this research was to investigate the mechanism by which human tumor-derived TGF-
 suppresses the immune function of human CD4+ T cells. This research was carried out using 
biological material (tumor effusions and T cells) from cancer patients, and T cells isolated from 
peripheral blood of healthy donors. The experimental design consisted of controlled laboratory in 
vitro studies and ex vivo analyses of patient cells as described below. No data were excluded from 
analyses. Experiments were performed at least three times using cells from independent human 
donors. Exact numbers of replicates are stated in the figure legends (n=x). 
Peripheral blood CD4+ T cell isolation, sorting and culture 
Bulk CD4+ T cells were isolated as described previously (37). Where indicated, flow cytometry-
sorted cell populations were used. T cell populations were sorted according to the expression of 
CD127, CD25, CD45RA and CCR7 to purify effector memory (EM) cells (CD127+CD25–CD45RA–
CCR7–). Purity was typically >90%. The following mAb were used: anti-CD45RA mAb–Pacific Blue 
(clone 2H4; Beckman Coulter, Brea, CA), anti-CD25 mAb–Brilliant Violet 605 (clone 2A3; BD 
Biosciences, Mountain View, CA), anti-CCR7 mAb–PE (clone FABP197; R&D Systems Europe, 
Abingdon, U.K.), and anti-CD127 mAb–allophycocyanin (clone eBioRDR5; eBioscience, San 
Diego, CA). Cells were (unless otherwise indicated) resuspended at 1 x 106/ml in RPMI1640 
containing 10% AB+ human serum, 50 U/ml penicillin and 50 mg/ml streptomycin (Invitrogen, 
Carlsbad, CA) (RPMI/10%AB), and 50 IU/ml rIL-2 (PeproTech, Rocky Hill, NJ). Where serum-free 
medium is indicated, AIM-V serum-free medium (Invitrogen) containing 50 IU/ml rIL-2 was used. 
Cells were activated where indicated by placing in cell culture plates pre-coated with anti-CD3 and 
anti-CD28 (1 g/ml and 5 g/ml, clones OKT-3 and CD28.2 respectively, Biolegend, London, U.K.) 
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for 72 hours. Activated cells were then washed and resuspended at 1 x 106/ml in RPMI/10%AB or 
AIM-V medium (as indicated) under experimental conditions described in the figure 
legend.Additions to cell culture included: TGF- (2-20 ng/ml) (Peprotech, Rocky Hill, NJ), 
Ivermectin (5 M, Sigma-Aldrich, Schnelldorf, Germany), SB-431542 (10 M, SelleckChem, 
Luzern, CH), Rapamycin (20ng/ml, (Merck), Oligomycin (1 M, Sigma-Aldrich), Rotenone (0.1 M, 
Sigma-Aldrich), 2-thenoyltrifluoroacetone (TTFA) (200 M, Sigma-Aldrich), Antimycin A (2 M, 
Sigma-Aldrich), Sodium Azide (10 M, Sigma-Aldrich), mouse IgG1 isotype control antibody (5 
g/ml, clone 11711 R&D Systems Europe), anti-TGF- mouse IgG1 monoclonal antibody (5 g/ml, 
clone 1D11, R&D Systems Europe). 
Tumor effusion samples 
Tumor effusion fluids were collected from cancer patients presenting with malignant effusions at the 
University Hospital Basel after obtaining written informed consent. After collection, the cellular 
components of the malignant effusions were separated by centrifugation and cells and fluids were 
frozen at -80°C until further use. Where indicated, total effusion cells were cultured or analyzed, and 
CD4+ T cells identified by staining with CD4-FITC (clone RPA-T4, BD Biosciences). Patient details 
are provided in Supplementary Table 1. 
RNA-mediated interference 
Activated primary human CD4+ T cells or Jurkat cells were transfected with pools of Smad2-specific 
siRNA or control scrambled siRNA (QIAGEN) for 72 hours using the AMAXA T cell nucleofection 
kit (Lonza). Knockdown efficiency was verified by Western blotting analysis. 
Extracellular metabolic flux analysis of intact cells and isolated mitochondria 
For analysis of the OCR (in pmol/min) and ECAR (in mpH/min), the Seahorse XFe96 metabolic 
extracellular flux analyzer was used (Seahorse Bioscience). Total or sorted CD4+ T cells were 
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resuspended in serum-free, unbuffered RPMI 1640 medium (Sigma-Aldrich) and were plated onto 
Seahorse cell plates (2.5 x 105 cells per well) coated with Cell-Tak (BD Biosciences) to enhance T 
cell attachment. Perturbation profiling of the use of metabolic pathways was done by the addition of 
oligomycin (1 M), carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 2 M), and 
rotenone (1 M; all are given as final concentrations, all from Sigma-Aldrich). For a description of 
how the various metabolic parameters were calculated, see fig. S1. The contribution of FAO to OCR 
was assessed by the addition of etomoxir (40 M, Sigma-Aldrich). Assessment of the OCR of isolated 
mitochondria was also performed with the Seahorse XFe96 metabolic extracellular flux analyzer and 
followed a protocol described previously (38). Sorted effector-memory CD4+ T cells were plated onto 
Seahorse cell plates, as described earlier, in RPMI/10%AB containing TGF- (5 ng/ml) where 
indicated in the figure legends and cultured at 37°C and 5%CO2 for 5 hours. The medium was then 
exchanged for mannitol and sucrose (MAS) buffer [70 mM sucrose, 220 mM mannitol, 10 mM 
KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA (pH 7.2), all reagents from Sigma-Aldrich] 
containing fatty acid–free bovine serum albumin (BSA, 4 mg/ml, Sigma-Aldrich). During the assay, 
first plasma membrane permeabilizer (PMP, 1 nM, Seahorse Bioscience) and then the following 
substrates (final concentrations given) together with ADP (1 mM) and FCCP (2 M, both from 
Sigma-Aldrich) were added: Complex I: Pyruvate (5 mM)/Malate (2.5 mM, both from Sigma-
Aldrich); Complex II: Succinate (10 mM, Sigma-Aldrich); Complex III: Duroquinol (0.5 mM, TCI 
America); Complex IV: tetramethyl-p-phenylenediamine (TMPD, 0.5 mM)/Ascorbate (2 mM, both 
from Sigma-Aldrich). Finally, the following specific inhibitors were added: Complex I: Rotenone (1 
M); Complex II: Malonate (40 M); Complex III: Antimycin A (20 M); Complex IV: Sodium 
Azide (20 mM, all from Sigma-Aldrich.) 
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Flow cytometric analysis of protein abundance and phosphorylation 
Phosphorylation of Smad2/3 was assessed in cells (0.2 x 106) previously fixed for 20 min at 37°C 
with fixation/permeabilization solution (BD Biosciences), permeabilized for 30 min at 4°C with 
Phosflow Perm Buffer III (BD Biosciences), and washed twice with phosphate-buffered saline (PBS) 
by staining for 30 min with Alexa Fluor 647–conjugated anti-pSmad2/3 (clone O72-670, BD 
Biosciences), further washing, and analysis. For assessment of IFN- production by intracellular 
cytokine staining, cells (0.2 x 106) were re-stimulated for 16 hours with soluble anti-CD3 and anti-
CD28 (1 and 5 g/ml, respectively) in culture conditions as indicated in the figure legends, and then 
treated for 4 hours with PMA (10 ng/ml; Sigma-Aldrich) and ionomycin (500 ng/ml; Sigma-Aldrich). 
During the final 2 hours of activation, the cells were treated with monensin (BioLegend) to block 
cytokine secretion. The cells were then washed and fixed for 20 min at 37°C with 
fixation/permeabilization solution and washed with permeabilization buffer before being stained for 
45 min phycoerythrin (PE)-conjugated anti-IFN- (clone B27, ImmunoTools), and then undergoing 
further washing and analysis. FoxP3 abundance was assessed in cells (0.2 x 106) previously fixed for 
20 min at 37°C in FoxP3 fixation/permeabilization solution (ebioscience) and washed with FoxP3 
permeabilization buffer (ebioscience) by staining for 45 min with anti-human FoxP3-PE (clone 
PCH101, ebioscience), which was followed by further washing and analysis. 
Detection of apoptosis 
Annexin V staining was performed to identify apoptotic cells by flow cytometry. Staining was 
performed using annexin V binding buffer (BD Biosciences) and FTIC-conjugated annexin V 
(ImmunoTools). 
ΔΨm measurement 
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MitoTracker staining was performed to assess differences in ΔΨm. Cells (0.2 x 106) were incubated 
in RPMI 1640/10% AB with 100 nM Mitotracker Green or MitoTracker Red (Invitrogen) for 20 min 
at 37°C and 5% CO2 before undergoing washing and analysis by flow cytometry. ΔΨm was 
calculated as follows: Mitotracker Red MFI / Mitotracker Green MFI. 
Quantification of mRNA 
The relative abundances of mRNAs of interested were quantified by real-time RT-PCR (qPCR). The 
mRNA was extracted with Qiagen spin columns (Qiagen) and cDNA was transcribed with the 
GoScript Reverse Transcription System (Promega) according to the manufacturer’s instructions. 
SYBR green or Taqman primers (Applied Biosystems) were used for qPCR analysis. See 
Supplementary Table 2 for further details. 
Western blotting analysis 
Cell lysates for Western blotting analysis were prepared in RIPA buffer (ThermoFischer Scientific) 
and protein concentrations were determined with a BCA protein assay kit (ThermoFischer Scientific). 
Whole-cell lysates were resolved by 4 to 15% SDS-PAGE and were transferred onto nitrocellulose 
membranes. The membranes were then incubated with the Total OXPHOS Human WB Antibody 
Cocktail (abcam, ab110411). The membranes were then stained with the appropriate secondary 
antibody IRDye 800CW–conjugated goat polyclonal antibody to rabbit IgG (926-32211) and IRDye 
800CW– or IRDye 680RD–conjugated goat polyclonal antibody to mouse IgG (926-68070); both 
from LI-COR). The Odyssey imaging system (LICOR) was used for band detection. 
Imaging flow cytometry 
MTR staining was performed as described earlier. Subsequently, cells (0.5 x 106) were fixed and 
stained for pSmad2/3 as described earlier. Finally, cells were resuspended in PBS with 300 nM DAPI 
(Molecular Probes) to stain nuclei and analyzed using the Imagestream X imaging flow cytometer. 
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Nuclear and mitochondrial masks were defined based on regions of DAPI/MTR intensity, 
respectively, and colocalization was calculated using analysis tools in IDEAS software. 
Biochemical assays of ETC function 
Complex I (ab109721), II (ab109908), IV (ab109909) and V (ab109714) function was assessed in 
lysates from 5 to 10 x 106 activated CD4+ T cells using the indicated kits from Mitosciences (abcam) 
according to the manufacturer’s instructions. 
Cytokine measurements in culture medium 
Cytokine production by T cells was measured using the Th1/Th2/Th17 Cytokine Bead Array 
(560484, BD Biosciences) or by ELISA for IFN- (ebiosciences) according to the manufacturers’ 
instructions. The amount of IFN- present in total tumor-associated cell cultures was normalized 
(based on flow cytometry phenotyping) for 50,000 CD4+ T cells. 
TGF- ELISA 
TGF- concentrations in cell culture medium were measured using the human TGF- ELISA set (BD 
Biosciences), according to the manufacturer’s instructions. 
Statistics 
Data were tested for normality with the Shapiro–Wilkins test. Data with normal distribution were 
assessed by paired Student two-sided t test. Multiple groups were compared by one- or two-way 
ANOVA, and a Bonferroni post-test for multiple comparisons. Non-normally distributed data were 
compared using a Wilcoxon test. Error bars represent SEM of the data presented. 
Study approval 
Blood samples were obtained from healthy donors after written informed consent. The study was 
approved by the Swiss Red Cross (blood transfusion service) and Institutional Review Board. Tumor 
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effusion fluids were collected from cancer patients presenting with malignant effusions at the 
University Hospital Basel after obtaining written informed consent. 
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Figure 1: Tumor-derived TGF-β inhibits EM CD4+ T cell IFN- production, requiring Smad 
phosphorylation but not nuclear translocation 
(A) Quantification of TGF-β levels in 11 tumor effusions (see Supplementary Table 1 for patient 
details). (B-F) Activated EM CD4+ T cells were restimulated for 16 hours in tumor supernatant (50% 
with 50% serum-free medium) with additionally either an isotype control antibody or TGF-β 
neutralizing mAb. (B) For each tumor effusion, comparisons were made of mean fold change in IFN-
 positive (+) cells (-TGF-β / isotype control mAb) as assessed by flow cytometry, corrected for 
dilution (factor 2) of tumor effusion fluid, with the concentration of TGF-β present in the sample (as 
described in Figure 1A/Supplementary Table 1) (n=11 pairs, each effusion tested on 3-5 
independent healthy donors), (C) percentage of IFN- producing (+) cells and (D) corrected fold 
increase of IFN- producing (+) cells; (E) abundance and (F) corrected fold change of IFN- secreted 
into the supernatant (C-F n=22, combined data for 8 tumor effusions (178, 222, 225, 280, 238, 164, 
193, 167), each tested on 3-6 independent donors). (G) percentage of IFN- producing (+) cells and 
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(H) Corrected fold change in IFN- positive (+) cells (-TGF-β / isotype control mAb) among 
activated EM CD4+ T cells, pre-treated for 30 min. with SB-431542 (10 M) or ivermectin (5 M) 
as indicated, then re-stimulated for 16 hours in presence of tumor effusion as described, plus isotype 
control (red dots/bars) or -TGF-β mAb (black dots/bars) at 21% oxygen (I,J) as for (G,H) but 
performed at 1% oxygen. Tumor effusions 178, 222, 225 and 167 were used (n = 14/15, at least n=3 
independent donors for each effusion). p values were calculated by: (B) Pearson correlation; (C,E) 
paired t test; (D,F) Wilcoxon test; (G-J) two-way ANOVA. *p<0.05, **p<0.01 ***p<0.0001. 
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Figure 2: TGF-β diminishes respiratory capacity of activated EM CD4+ T cells  
(A) OCR profile, (B) basal OCR, (C) ATP-coupled OCR, (D) SRC and (E) % of control ATP-
Coupled and Maximal OCR; (F) ECAR, (G) basal and (H) maximal ECAR of activated EM CD4+ T 
cells, treated for 16 hours with either control medium (black line) or TGF-β (5 ng/ml, red line) as 
indicated, then assessed for metabolic parameters as described in Supplementary Figure 2 (n=4 
independent donors). (I) ATP-coupled OCR/basal ECAR (OCR/ECAR) ratio of activated EM CD4+ 
T cells treated as in (A-F) (n=4 independent donors). (J-K) ATP-coupled OCR and basal ECAR of 
(J) total primary CD4+ T cells (n=9 independent donors) or (K) Jurkat T cells (n=3 biological 
replicates), transfected with Smad2 or control scrambled siRNA and then treated with TGF-β-treated 
as in (A-I) (expressed as a percentage of rates under control treatment in absence of TGF-β). (L) 
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Percentage of Annexin V positive (+) cells amongst activated EM CD4+ T cells treated as in (A-F) 
(n=5 independent donors). All p values were calculated by paired t test. *p<0.05. 
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Figure 3: Smad proteins are present in mitochondria of CD4+ T cells 
(A) mRNA levels in activated, total CD4+ T cells, quantified relative to ribosomal 18s RNA and 
expressed as relative quantities (RQ) compared to control treatment for the genes indicated, under 
control treatment (Ctrl., black bars) or TGF-β treatment (5 ng/ml, red bars) for 5 or 24 hours as 
indicated (n=6 independent donors). (B) Example Western Blot (non-contiguous lanes) and summary 
data (expressed relative to actin abundance) for mitochondrial electron transport chain (ETC) 
complex I-V protein expression in activated, total CD4+ T cells, under control treatment (Ctrl., black 
bars) or TGF-β treatment (5 ng/ml, red bars) for 24 hours (n=5 independent donors). ml(C) Example 
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images of activated, total control (lower) CD4+ T cells or cells treated with TGF-β (5 ng/ml) for 1 
hour (upper), then stained with mitotracker red (MTR, red), DAPI (blue) and anti-pSmad2/3 
(turquoise), and analyzed using Imagestream X. (D) Summary data of mean fluorescence intensity 
(MFI) in mitochondria / MFI in nuclei of the fluorochromes indicated, in total CD4+ T cells treated 
with TGF-β as in (F) (n=4 independent donors, MFIs of >2000 cells per condition and per donor). 
(E) Summary data of pSmad2/3 mean fluorescence intensity (MFI) on defined mitochondrial and 
nuclear regions in control (Ctrl., black bars) and TGF-β-treated (5 ng/ml, red bars) CD4+ T cells (n=4 
independent donors). (F) Fold increase in pSmad2/3 MFI in mitochondrial and nuclear regions of 
total CD4+ T cells treated as in (E) (n=4 independent donors). (G) pSmad2/3 MFI assessed by flow 
cytometry (black bars, left y axis) of tumor-associated CD4+ T cells (from effusions 178, 225 and 
201) stained ex vivo, compared with effusion TGF-β concentration (red bars, right y axis). (H) 
Example images (from sample 201) of CD4+ T cells (gated on CD4) among tumor-associated cells, 
stained ex vivo with mitotracker red (MTR, red), DAPI (blue) and anti-pSmad2/3 (turquoise), and 
analyzed using Imagestream X. (I) Summary data of (MFI) in mitochondria / MFI in nuclei in cells 
treated as in (H) (n=3 independent donors, MFIs of >2000 cells per donor). p values were calculated 
by: (A) Wilcoxon test, (B,F) paired t test, (D) one-way ANOVA, (E) two-way ANOVA. *p<0.05 
**p<0.01. 
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Figure 4: TGF-β specifically inhibits activity of ATP-Synthase  
(A) Mean OCR of activated, EM CD4+ T cells treated for 5 hours either with control medium (Ctrl., 
black bars) or TGF-β (5 ng/ml, red bars), then permeabilized to assess mitochondrial respiration of 
specific substrates or in response to electron donors provided for complex I, II, III and IV (n=8 
independent donors). (B) Mean activity of complexes I, II, IV and V as assessed by biochemical assay 
in activated, total CD4+ T cells treated for 5 hours either with control medium (Ctrl., black bars) or 
TGF-β (5 ng/ml, red bars) (n=10 independent donors). (C) Mitochondrial membrane potential (ΔΨm) 
of activated, total CD4+ T cells, expressed as a ratio of Mitospy Orange Mean Fluorescence Intensity 
in untreated vs. FCCP-treated cells previously treated with control medium or TGF-β as in (B) (n=4 
independent donors). p values were calculated by: (A) Wilcoxon test; (B,C) paired t test;. *p<0.05, 
***p<0.0001. 
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Figure 5: TGF-β inhibits EM CD4+ T cell IFN- expression independently of nuclear Smad 
import, but depending on mitochondrial respiration 
(A) IFN-, TNF-, IL-10, IL-17A and IL-4 secreted by activated EM CD4+ T cells restimulated for 
16 hours in control medium (Ctrl., black bars) or treated with TGF-β (5 ng/ml, red bars), and measured 
from supernatant by CBA (n=6 independent donors). (B) MFI of isotype control antibody staining or 
anti-pSmad2/3 antibody staining in activated, total CD4+ T cells, pre-treated with ivermectin (5 M) 
or SB-431542 (10 M) for 30 min., then treated for 1 hour with control medium (black bars) or TGF-
β (5 ng/ml red bars) (n=3 independent donors). (C) Fold increase in colocalization of fluorescence 
between DAPI (nuclear marker) and pSmad2/3 in cells treated as in (B) (n=4 independent donors). 
(D) mRNA levels, quantified relative to ribosomal 18s RNA and expressed as relative quantities 
(RQ), compared to control treatment for TBX21 or IFNG in total, activated CD4+ T cells, pre-treated 
for 30 min. with ivermectin or SB-431542 as indicated then cultured for 16 hours, with either control 
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medium (Ctrl., black bars) or TGF-β (5 ng/ml, red bars) (n=3 independent donors). (E) Percentage 
IFN- positive (+) cells among activated EM CD4+ T cells pre-treated for 30 min. with ivermectin or 
SB-431542 as indicated, then re-stimulated overnight in the presence of control medium (Ctrl., black 
bars) or TGF-β (5 ng/ml, red bars) (n=5 independent donors). (F) IFN- content of supernatants from 
tumor-associated cells, stimulated overnight with anti-CD3/anti-CD28 mAb in the presence of TGF-
β (level as per effusion, see Fig. 1A and Tbl. 1), plus additionally either an isotype control antibody 
(red bars) or TGF-β neutralizing mAb (black bars), performed either in control conditions (right 
panel, n=3 independent donors) on in presence of ivermectin (5 M, left panel, n=2 independent 
donors, < Det. = below assay detection limit). (G) Percentage IFN- producing (+) cells among 
activated EM CD4+ T cells restimulated for 16 hours in control medium (Ctrl., black bar) or in 
presence of Oligomycin (1 μM, blue bar) (n=5 independent donors).  (H) IFN- measured from cell 
culture supernatants of EM CD4+ T cells, treated as in (H) (n=8 independent donors). (I) IFN- 
measured from cell culture supernatants of EM CD4+ T cells restimulated for 16 hours in control 
medium or in presence of TGF-β and/or Oligomycin as indicated (n=4 independent donors) (J) 
Percentage of IFN- producing (+) cells among activated EM CD4+ T cells restimulated for 16 hours 
at 1% atmospheric oxygen in control medium (Ctrl., black bar) or in presence of TGF-β (5 ng/ml, red 
bar) or Oligomycin (1 μM, blue bar) (n=5 independent donors). (K,L) IFN- measured from cell 
culture supernatants of EM CD4+ T cells, treated as in (J) (n=6-8 independent donors). p values 
calculated by (A,H,I,K,L) paired t test, (B,D,E,F) two-way ANOVA, (C,J) one-way ANOVA. 
*p<0.05. 
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Figure 6: Tumor-derived TGF-β inhibits EM CD4+ T cell metabolism 
(A) OCR and ECAR of activated EM CD4+ T cells pre-incubated for 5 hours in tumor supernatant 
(50% with 50% serum-free medium) with additionally either an isotype control antibody (red line), 
or TGF-β neutralizing mAb (-TGF-β, black line), additionally treated with Oligomycin (Oli. 1μM), 
FCCP (2 μM) and Rotenone (1 μM) as indicated to measure metabolic parameters as described in 
Supplementary Figure 1 (representative example with effusion 178). (B) Fold change in ATP-
coupled OCR and basal ECAR in cells treated as in (A), isotype control antibody (red circles) TGF-
β neutralizing mAb (-TGF-β, black circles) (n=7 independent donors, combined data for 
experiments with effusion 178 and 225). (C) ATP-coupled OCR/basal ECAR ratios of cells treated 
as in (A). p values were calculated by (B) Wilcoxon Test (C) paired t test. *p<0.05 
